- Conditions
- Nasal Polyposis, Eosinophilic Chronic Rhinosinusitis
- Interventions
- Benralizumab 30 mg, Matched placebo
- Biological
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 295 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2025
- U.S. locations
- 15
- States / cities
- Huntington Beach, California • Grand Junction, Colorado • Gainesville, Florida + 12 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–9
of 9
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Asthma
- Interventions
- Tezepelumab (APFS), Tezepelumab (AI)
- Biological
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 12 Years to 80 Years
- Enrollment
- 216 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2020
- U.S. locations
- 16
- States / cities
- Hoover, Alabama • Gilbert, Arizona • Northridge, California + 12 more
- Conditions
- Chronic Rhinosinusitis With Nasal Polyps
- Interventions
- Experimental: Tezepelumab, Placebo, Mometasone furoate or equivalent intranasal corticosteroid
- Biological · Other · Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 416 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 21
- States / cities
- Birmingham, Alabama • Bakersfield, California • Newport Beach, California + 18 more
- Conditions
- Nasal Polyposis
- Interventions
- Benralizumab 30 mg SC + Mometasone Furoate, Matching placebo SC + Mometasone Furoate
- Biological
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 413 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2020
- U.S. locations
- 48
- States / cities
- Birmingham, Alabama • Fresno, California • Huntington Beach, California + 37 more
- Conditions
- Asthma, Eosinophilic Granulomatosis With Polyangiitis (EGPA), Hypereosinophilic Syndrome (HES)
- Interventions
- Benralizumab
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 6 Years and older
- Enrollment
- 230 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 8
- States / cities
- Aurora, Colorado • Bethesda, Maryland • Ann Arbor, Michigan + 5 more
- Conditions
- APOL1-Mediated Kidney Disease
- Interventions
- AZD2373-Arm 1, AZD2373-Arm 2, Placebo, APOL1 Genotyping Clinical Trial Assay
- Combination Product · Device
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 63 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 86
- States / cities
- Alabaster, Alabama • Birmingham, Alabama • Irondale, Alabama + 73 more
- Conditions
- Asthma
- Interventions
- Benralizumab
- Biological
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 162 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2016
- U.S. locations
- 12
- States / cities
- Fountain Valley, California • Walnut Creek, California • Celebration, Florida + 9 more
- Conditions
- Cutaneous Lupus Erythematosus
- Interventions
- Anifrolumab, Placebo
- Combination Product · Other
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 339 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 34
- States / cities
- Phoenix, Arizona • Covina, California • La Jolla, California + 28 more
- Conditions
- Healthy Participants Study
- Interventions
- Anifrolumab, Autoinjector, Accessorized Pre-Filled Syringe
- Drug · Device
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 180 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2023
- U.S. locations
- 1
- States / cities
- Brooklyn, Maryland